MK-1439A
Total Payments
$2.6M
Transactions
1,700
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $2.6M | 1,700 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 1,698 | 100.0% |
| Consulting Fee | $1,088 | 2 | 0.0% |
Payments by Type
Research
$2.6M
1,698 transactions
General
$1,088
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | Merck Sharp & Dohme Corporation | $1.6M | 0 |
| A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors NRTIs | Merck Sharp & Dohme Corporation | $924,100 | 0 |
| A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Na ve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor NNRTI Transmitted Resistance Mutations | Merck Sharp & Dohme Corporation | $17,284 | 0 |
Top Doctors Receiving Payments for MK-1439A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $2.6M | 1,698 |
| , MD | Hematology & Oncology | San Francisco, CA | $650.00 | 1 |
| Ann Collier | Infectious Disease | Seattle, WA | $438.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.6M
- Total Doctors 2
- Transactions 1,700
About MK-1439A
MK-1439A is a drug associated with $2.6M in payments to 2 healthcare providers, recorded across 1,700 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $2.6M was paid across 1,700 transactions to 2 doctors.
The most common payment nature for MK-1439A is "Unspecified" ($2.6M, 100.0% of total).
MK-1439A is associated with 3 research studies, including "A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects" ($1.6M).